BTK and B-cell chronic lymphocytic leukemia: This obvious reliance of CLL cells on both ligand-dependent and ligand-independent BCR signals has led to the establishment of inhibitors against BCR pathway kinases, targeting Syk, Btk and Lyn for CLL treatment, with great clinical success [13–16].